| HOME >> MEDICINE >> TECHNOLOGY |
5.2 How Will the Balance of Market Share Shift During the Forecast Period?
5.3 Dopaminergic Agents: The Foundation of Parkinson's Disease Treatment
5.3.1 Levodopa and Carbidopa
5.3.2 Brands of Dopaminergic Agent
5.3.3 Use of Dopaminergic Agents Will Remain Central to Parkinson's Disease Management
5.3.4 A New Commercial Life for Dopaminergic Agents?
5.3.5 Market Projection for Dopaminergic Agents, 2012-2023
5.4 Dopamine Receptor Agonists: The Leading Class in 2011
5.4.1 Mechanism of Action Makes Dopamine Receptor Agonists a Good First-Line Therapy
5.4.2 Multiple Products Exist in the Dopamine Receptor Agonists Class
5.4.3 A Thin Pipeline in this Segment
5.4.4 Commercial Opportunities for Dopamine Receptor Agonists
5.4.5 Market Projection for Dopamine Receptor Agonists, 2012-2023
5.5 COMT Inhibitors: The Segment with the Leading Product in 2011
5.5.1 COMT Inhibitors as Adjuncts to Dopaminergic Agents
5.5.2 Limitations of COMT Inhibitors
5.5.3 Future Commercial Scope for COMT Inhibitors
5.5.4 Market Projection for COMT Inhibitors, 2012-2023
5.6 MAO Inhibitors: A Growing Segment
5.6.1 Another Useful Adjunct to Levodopa
5.6.2 MAO Inhibitors Have Advantages over COMT Inhibitors
5.6.3 Potential for New Growth in the Sector
5.6.4 Market Projection for MAO Inhibitors, 2012-2023
5.7 Other Mechanisms of Action: The Major Driver for the Market
5.7.1 A Broad and Diverse Segment
5.7.2 The Key New Mechanisms of Action
5.7.3 Market Projection for Other Mechanisms of Action, 2012-2023
6. R&D Pipeline for Treating Parkinson's Disease, 2012
6.1 New Mechanisms of Action in the Late-Stage Pipeline6.2 The Phase 3 Pipeline: Overview6.3 Rytary (Impax Laboratories): The Next Version of Levodopa to Reach the Market6.3.1 FDA De
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |